Jesse Erasmus
@jesseerasmus.bsky.social
Director of Virology at HDT Bio. Developing RNA platform for emerging infectious diseases. 🇿🇦🇰🇷
New paper out describing how we developed a 2-antigen repRNA vaccine for #CCHF in our continuing collaboration with NIAID (David Hawman and Heinz Feldmann). www.sciencedirect.com/science/arti...
October 1, 2025 at 12:32 AM
Another update on our #CCHF vaccine that is marching towards phase I clinical trial. Here we report on the durability of protection in a mouse model of CCHFV infection. Excellent work from our colleagues at RML/NIAID🧪 www.nature.com/articles/s41...
Replicating RNA vaccine confers durable immunity against Crimean Congo hemorrhagic fever virus challenge in mice - npj Vaccines
npj Vaccines - Replicating RNA vaccine confers durable immunity against Crimean Congo hemorrhagic fever virus challenge in mice
www.nature.com
October 1, 2025 at 12:31 AM
Some related posts below. bsky.app/profile/jess...
Just published! Here we report immunogenicity and efficacy of our replicon RNA vaccine against Crimean-Congo hemorrhagic fever in a cynomolgus macaque model of #CCHFV infection. Stay tuned as we advance this candidate in clinical trials.
www.thelancet.com/journals/ebi...
www.thelancet.com/journals/ebi...
A replicating RNA vaccine confers protection against Crimean-Congo hemorrhagic fever in cynomolgus macaques
Our data demonstrate that our repNP vaccine and NP-specific antibody can protect against
CCHFV in non-human primates.
www.thelancet.com
October 1, 2025 at 12:30 AM
Some related posts below. bsky.app/profile/jess...
Seems heads are already rolling.
August 8, 2025 at 8:16 PM
Seems heads are already rolling.
Without safety concern but still higher reactogenicity across the board compared to the licensed comparator. Wish there was a way to improve efficacy while retaining the favorable safety profile of the licensed comparator 🤔
July 2, 2025 at 2:06 AM
Without safety concern but still higher reactogenicity across the board compared to the licensed comparator. Wish there was a way to improve efficacy while retaining the favorable safety profile of the licensed comparator 🤔
Congrats! Super cool finding. Now I want to put gH-UL116-UL141 into our RNA platform and compare to all the other permutations of structural (and now “nonstructural”) antigen candidates.
July 1, 2025 at 2:32 PM
Congrats! Super cool finding. Now I want to put gH-UL116-UL141 into our RNA platform and compare to all the other permutations of structural (and now “nonstructural”) antigen candidates.
No I haven’t. I’ll check it out!
June 19, 2025 at 1:36 AM
No I haven’t. I’ll check it out!
Nothing published on this yet. But we are working on it!
May 21, 2025 at 11:47 AM
Nothing published on this yet. But we are working on it!
Summary:
1) LION/repRNA (don’t confuse with LNP/mRNA) can indeed confer protection on par with the VSV platform (at least in guinea pigs) after one shot.
2) LION & VSV elicited similar IgG titers but with a unique effector profile. LION induced higher ADCP & ADNP activity but lower ADCD. (2/2)
1) LION/repRNA (don’t confuse with LNP/mRNA) can indeed confer protection on par with the VSV platform (at least in guinea pigs) after one shot.
2) LION & VSV elicited similar IgG titers but with a unique effector profile. LION induced higher ADCP & ADNP activity but lower ADCD. (2/2)
May 6, 2025 at 1:58 PM
Summary:
1) LION/repRNA (don’t confuse with LNP/mRNA) can indeed confer protection on par with the VSV platform (at least in guinea pigs) after one shot.
2) LION & VSV elicited similar IgG titers but with a unique effector profile. LION induced higher ADCP & ADNP activity but lower ADCD. (2/2)
1) LION/repRNA (don’t confuse with LNP/mRNA) can indeed confer protection on par with the VSV platform (at least in guinea pigs) after one shot.
2) LION & VSV elicited similar IgG titers but with a unique effector profile. LION induced higher ADCP & ADNP activity but lower ADCD. (2/2)
Mice were protected from death and viremia (panels d and e) in the inactivated vaccine group but not from morbidity (panels b and c), suggesting some nuance in the quality of immune response between authentic and inactivated versions. Lots of potential explanations out there.
May 4, 2025 at 4:14 PM
Mice were protected from death and viremia (panels d and e) in the inactivated vaccine group but not from morbidity (panels b and c), suggesting some nuance in the quality of immune response between authentic and inactivated versions. Lots of potential explanations out there.
In fig 5 of the 🔗 paper, I compared the durability of protective immunity elicited by same doses of the exact same virus/vaccine (non replicating). One was inactivated with formalin (open circles); the other was not (closed circles). Inactivation killed durability. www.nature.com/articles/nm....
May 4, 2025 at 4:09 PM
In fig 5 of the 🔗 paper, I compared the durability of protective immunity elicited by same doses of the exact same virus/vaccine (non replicating). One was inactivated with formalin (open circles); the other was not (closed circles). Inactivation killed durability. www.nature.com/articles/nm....